Credit Suisse (SIX:CSGN) analyst Jailendra Singh maintained a Hold rating on Clover Health Investments on Wednesday, setting a price target of $9, which is approximately 20.48% above the present share price of $7.47.
Singh expects Clover Health Investments to post earnings per share (EPS) of -$0.20 for the second quarter of 2021.
The current consensus among 3 TipRanks analysts is for a Moderate Buy rating of shares in Clover Health Investments, with an average price target of $9.33.
The analysts price targets range from a high of $10 to a low of $9.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $166.23 million and a net profit of -$67.63 million. The company's market cap is $3.07 billion.
According to TipRanks.com, Credit Suisse analyst Jailendra Singh is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 8.2% and a 45.71% success rate.
Social Capital Hedosophia Holdings Corp III is a blank check company. It is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.